Opinion|Videos|July 17, 2024
Evaluating Amivantamab and Lazertinib: Key Findings from the CHRYSALIS-2 Study at ASCO 2024
Author(s)Jason Porter, MD
A key opinion leader examines the combination therapy of amivantamab and lazertinib in the CHRYSALIS-2 study for treatment-naïve patients or those with 2 or more prior lines of therapy, and its potential implications for non-small cell lung cancer treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Discuss the data that was presented at the ASCO 2024 on combination use amivantamab and lazertinib in the CHRYSALIS-2 study for patients who were treatment-naïve or had ≤ 2 prior lines.
- Based on this study, how do you think amivantamab plus lazertinib compares with other current therapies used for EGFR mutations in NSCLC?
- How might the safety data from this study impact treatment decisions and management strategies in clinical practice?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Special Report: The Oncology Care Model, 10 Years Later
2
FDA Approves Tocilizumab-bavi for CAR-T-Induced CRS, Pediatric COVID-19
3
AI Model Challenges Genomic Classifiers in Early Breast Cancer Risk Stratification: Nancy Lin, MD
4
Weight Loss Drugs Can Improve Outcomes in Patients With Heart Failure and Obesity: Sandra Chaparro, MD
5